Molecular Function of cGAS-STING in SARS-CoV-2: A Novel Approach to COVID-19 Treatment

Biomed Res Int. 2022 Nov 22:2022:6189254. doi: 10.1155/2022/6189254. eCollection 2022.

Abstract

Coronavirus illness 2019 is a significant worldwide health danger that began with severe acute respiratory syndrome coronavirus two infections. It is the largest pandemic of our lifetime to date, affecting millions of people and crippling economies globally. There is currently no viable therapy for this devastating condition. The fast spread of SARS-CoV-2 underlines the critical need for favorable treatments to prevent SARS-CoV-2 infection and dissemination. Regulating the upstream cytokine release might be a possible method for COVID-19 therapy. We propose that more consideration be paid to the dysregulated IFN-I release in COVID-19 and that cGAS and STING be considered therapeutic targets for avoiding cytokine storms and as critical components in host antiviral defense mechanisms.

Publication types

  • Review

MeSH terms

  • COVID-19 Drug Treatment*
  • Humans
  • Membrane Proteins*
  • Nucleotidyltransferases*
  • Pandemics
  • SARS-CoV-2*

Substances

  • Nucleotidyltransferases
  • cGAS protein, human
  • STING1 protein, human
  • Membrane Proteins